Policy / Pricing Joint MHRA/NICE pathway ‘benefits industry over patients’ PharmaphorumLSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.Read full story pharminent May 14, 2026 (Last updated: May 16, 2026) Pharmaphorum LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA’s leadership void leaves biotech with renewed ‘uncertainty’Next: Pfizer receives EC approval for Hympavzi to treat haemophilia Related Stories Policy / Pricing Biotech leaders pitch Pazdur as next FDA chief pharminent May 14, 2026 Policy / Pricing FDA’s leadership void leaves biotech with renewed ‘uncertainty’ pharminent May 13, 2026 Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
